Corcept falls after phase 3 results on Cushing's candidate doesn't include some data

Published on 22 Apr 2024 on Seeking Alpha

Corcept Therapeutics (CORT) reports positive phase 3 trial results for Cushing's syndrome candidate,...

Read the rest of the article

Start tracking your investments with Statfolio

Corcept Therapeutics Incorporated CORT recently announced the submission of a new drug applicatio...

Zacks · via Yahoo Finance 31 Dec 2024

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we...

Insider Monkey · via Yahoo Finance 25 Dec 2024

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating i...

Zacks · via Yahoo Finance 12 Dec 2024

Our time-tested methodologies were at work to help investors navigate the market well last week....

Zacks · via Yahoo Finance 25 Nov 2024

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months agai...

Zacks · via Yahoo Finance 22 Nov 2024

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst...

Benzinga · via Yahoo Finance 30 Sep 2024

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript May 1, 2024 Corc...

Insider Monkey via Yahoo Finance 2 May 2024

Corcept Therapeutics Incorporated CORT reported first-quarter 2024 earnings of 25 cents per share...

Zacks via Yahoo Finance 2 May 2024

Small-cap and midcap U.S. stocks are trading relatively low to historical price-to-earnings...

Market Watch 23 Apr 2024

Corcept Therapeutics (CORT) reports positive phase 3 trial results for Cushing's syndrome candida...

Seeking Alpha 22 Apr 2024